Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000950170-25-097749·CASI Pharmaceuticals, Inc.
Schedule 13G ownership disclosure
CASI PHARMACEUTICALS INC
Ordinary Shares · CUSIP: G1933S101
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Panacea Venture Healthcare Fund II, L.P.
Shares: 2,050,000 · Class: 13.2%
- Panacea Venture Healthcare Fund II GP Company, Ltd.
Shares: 2,050,000 · Class: 13.2%
- Panacea Innovation Limited
Shares: 2,050,000 · Class: 13.2%
- James Huang
Shares: 2,161,571 · Class: 13.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-097749
- Form type
- SCHEDULE 13G/A
- Filer
- CASI Pharmaceuticals, Inc.
- CIK
- CIK 1962738
- Filed
- Jul 23, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership